ABVC BioPharma, Inc. (ABVC)
Largest Insider Buys in Sector
ABVC Stock Price History Chart
ABVC Stock Performance
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Insider Activity of ABVC BioPharma, Inc.
Over the last 12 months, insiders at ABVC BioPharma, Inc. have bought $0 and sold $0 worth of ABVC BioPharma, Inc. stock.
On average, over the past 5 years, insiders at ABVC BioPharma, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $1,500 was made by Nirta Joseph (director) on 2010‑05‑11.
List of Insider Buy and Sell Transactions, ABVC BioPharma, Inc.
| 2010-05-11 | director | 10,000 0.0305% | $0.15 | $1,500 | ||||
| 2010-03-22 | director | 2,000 0.0061% | $0.26 | $520 | ||||
| 2009-10-01 | 10 percent owner | 240 – | $0.42 | $101 | ||||
| 2009-04-14 | 21 <0.0001% | $0.75 | $16 | |||||
| 2009-01-23 | Sale | 4M 13.8448% | $1.00 | $4M | ||||
| 2009-01-23 | 4M 13.8448% | $1.00 | $4M | |||||
| 2008-08-18 | Sale | CEO | 1.5M 0.3123% | $1.00 | $1.5M | |||
| 2007-07-30 | VP New Product Development | 3M – | $0 | $0 |